August 6, 2020 -- Precigen is highlighting clinical results from a phase I trial conducted by its subsidiary Precigen Triple-Gene that show that its multigenic investigational therapeutic agent for heart failure improves patient outcomes.
Precigen's Inxn-4001 investigational therapy uses a nonviral plasmid to express SDF-1α, VEGF165, and S100A1 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling. The therapy targets "molecular mechanisms of pathological myocardial remodelling and is delivered to the ventricle via retrograde coronary sinus infusion (RCSI)," it said.
The phase I trial included 12 chronic heart failure patients treated in two cohorts who received different amounts of the drug, then were evaluated after six months. The Inxn-4001 infusions were well-tolerated and no adverse events were attributed to them, the company said. Secondary findings demonstrated that 50% of patients showed improved results in a six-minute walk test at six-month follow up, according to the firm.
Additional clinical results are expected within the next 12 months.